Back to Search Start Over

Precision Phenotyping of Dilated Cardiomyopathy Using Multidimensional Data

Authors :
Upasana Tayal
Job A.J. Verdonschot
Mark R. Hazebroek
James Howard
John Gregson
Simon Newsome
Ankur Gulati
Chee Jian Pua
Brian P. Halliday
Amrit S. Lota
Rachel J. Buchan
Nicola Whiffin
Lina Kanapeckaite
Resham Baruah
Julian W.E. Jarman
Declan P. O’Regan
Paul J.R. Barton
James S. Ware
Dudley J. Pennell
Bouke P. Adriaans
Sebastiaan C.A.M. Bekkers
Jackie Donovan
Michael Frenneaux
Leslie T. Cooper
James L. Januzzi
John G.F. Cleland
Stuart A. Cook
Rahul C. Deo
Stephane R.B. Heymans
Sanjay K. Prasad
RS: Carim - H02 Cardiomyopathy
Cardiologie
MUMC+: MA Med Staf Artsass Cardiologie (9)
RS: Carim - B06 Imaging
RS: Carim - H01 Clinical atrial fibrillation
MUMC+: MA Cardiologie (9)
MUMC+: MA Med Staf Spec Cardiologie (9)
FONDATION LEDUCQ
Imperial College Healthcare NHS Trust- BRC Funding
Source :
Journal of the American College of Cardiology, 79(22), 2219-2232. Elsevier Science
Publication Year :
2022

Abstract

BACKGROUND: Dilated cardiomyopathy (DCM) is a final common manifestation of heterogenous etiologies. Adverse outcomes highlight the need for disease stratification beyond ejection fraction. OBJECTIVES: The purpose of this study was to identify novel, reproducible subphenotypes of DCM using multiparametric data for improved patient stratification. METHODS: Longitudinal, observational UK-derivation (n = 426; median age 54 years; 67% men) and Dutch-validation (n = 239; median age 56 years; 64% men) cohorts of DCM patients (enrolled 2009-2016) with clinical, genetic, cardiovascular magnetic resonance, and proteomic assessments. Machine learning with profile regression identified novel disease subtypes. Penalized multinomial logistic regression was used for validation. Nested Cox models compared novel groupings to conventional risk measures. Primary composite outcome was cardiovascular death, heart failure, or arrhythmia events (median follow-up 4 years). RESULTS: In total, 3 novel DCM subtypes were identified: profibrotic metabolic, mild nonfibrotic, and biventricular impairment. Prognosis differed between subtypes in both the derivation (P < 0.0001) and validation cohorts. The novel profibrotic metabolic subtype had more diabetes, universal myocardial fibrosis, preserved right ventricular function, and elevated creatinine. For clinical application, 5 variables were sufficient for classification (left and right ventricular end-systolic volumes, left atrial volume, myocardial fibrosis, and creatinine). Adding the novel DCM subtype improved the C-statistic from 0.60 to 0.76. Interleukin-4 receptor-alpha was identified as a novel prognostic biomarker in derivation (HR: 3.6; 95% CI: 1.9-6.5; P = 0.00002) and validation cohorts (HR: 1.94; 95% CI: 1.3-2.8; P = 0.00005). CONCLUSIONS: Three reproducible, mechanistically distinct DCM subtypes were identified using widely available clinical and biological data, adding prognostic value to traditional risk models. They may improve patient selection for novel interventions, thereby enabling precision medicine. ispartof: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY vol:79 issue:22 pages:2219-2232 ispartof: location:United States status: published

Details

Language :
English
ISSN :
07351097 and 20092016
Volume :
79
Issue :
22
Database :
OpenAIRE
Journal :
Journal of the American College of Cardiology
Accession number :
edsair.doi.dedup.....c1783dcba7d8f4c62fabc35aca6d2f21